Evolus, Inc.

Evolus, Inc. is a U.S.-based performance beauty company focused on cash-pay medical aesthetics. It commercializes Jeuveau®, a botulinum toxin for glabellar lines, and has begun launching Evolysse™, a line of injectable hyaluronic acid gels for wrinkles and folds.

−8,5 %

66,3 %

−17,4 %

+11,6 %

1.90

1.54

— Evolus, Inc.
%
Injectable neurotoxins85% Jeuveau® is the company's commercial botulinum toxin product used by aesthetic practitioners for glabellar lines.
Injectable hyaluronic acid gels15% Evolysse™ is a collection of HA fillers for wrinkles, folds, and facial contour applications.
Commercial support programs0% Loyalty, pricing, and co-branded marketing programs that support practitioner adoption and repeat purchasing.

Evolus sells primarily to licensed aesthetic practitioners who administer injectable treatments in the cash-pay beauty...

  • Licensed aesthetic practitionersprimary

    Buy Jeuveau® and Evolysse™ to perform elective injectable treatments and retain patients in cash-pay aesthetics.

  • Medical spas and aesthetic clinicsprimary

    Purchase products for recurring facial aesthetic procedures and respond to pricing, loyalty, and bundled offers.

  • Dermatology and plastic surgery practicessecondary

    Use the products as part of broader aesthetic service menus and value clinical data and product differentiation.

  • International distribution partnerssecondary

    Help commercialize Jeuveau® and future Evolysse™ launches outside the U.S. where direct sales are not used.

Evolus is headquartered in the United States and generates most revenue there, with Jeuveau® also sold in Canada,...

  • •United States is the main commercial market for Jeuveau® and Evolysse™
  • •Canada contributes service revenue through a distribution partner
  • •Certain European countries and Australia are current Jeuveau® markets
  • •Europe is a key expansion market for the Evolysse™ collection
  • •Manufacturing is outsourced to South Korea and France

Evolus is building a cash-pay aesthetics franchise around Jeuveau® and the Evolysse™ filler line, using an...

01
Grow Jeuveau® adoption in the U.S. and abroadshort-term

Jeuveau® is the core commercial product and funds the platform.

02
Scale Evolysse™ in the U.S. and Europemedium-term

The HA filler line expands the addressable market and diversifies revenue.

03
Expand the product portfolio through approvals and partnershipsmedium-term

A broader portfolio improves customer retention and competitive positioning.

Evolus depends on continued adoption of elective aesthetic procedures, so consumer spending weakness, inflation, and...

high

Dependence on elective consumer spending

Customers pay out of pocket, so demand is sensitive to confidence, inflation, and economic stress.

Scope
Jeuveau® and Evolysse™ procedure volumes
Materiality
high
high

Tariffs and supply-chain cost inflation

The company imports products and components through third-party manufacturers, making costs vulnerable to trade actions.

Scope
Gross margin and inventory planning
Materiality
high
high

Regulatory approval and launch timing

Future Evolysse™ products require FDA and other approvals before commercialization.

Scope
Revenue timing and product pipeline
Materiality
high
medium

Manufacturing concentration

Jeuveau® and Evolysse™ rely on Daewoong and Symatese for production and supply.

Scope
Product availability and quality control
Materiality
high
medium

Competitive pricing pressure

Large aesthetics competitors can use rebates, coupons, and bundling to defend share.

Scope
Market share and average selling price
Materiality
medium
Revenue recognition and net revenue adjustments
Net revenue and gross margin
Service revenue in Canada
Revenue mix and margin presentation
Contingent royalty obligation fair value
Operating expenses and balance sheet liabilities
Inventory and launch-related build
Working capital and cash flow

Evolent Health, Inc.

EVH · Services-Management Services

Evolution

EVO.ST · Consumer Discretionary

AbbVie Inc.

ABBV · Pharmaceutical Preparations

Evolv Technologies Holdings, Inc.

EVLV · Computer Peripheral Equipment, NEC

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

Evommune, Inc.

EVMN · Pharmaceutical Preparations

: 28/04/2026